In vitro and in vivo antithrombotic activity of PD-198961, a novel synthetic factor Xa inhibitor

Journal of Cardiovascular Pharmacology

Volumn 44, Issue 4, 2004, Pages 493-500

  Chi, Liguo ^a   Peng, Yun Wen ^a   Gibson, Glenn ^a   Hicks, Gary ^a   Mertz, Thomas E ^a   Rapundalo, Stephen ^a   Janiczek, Nancy ^a   Edmunds, Jeremy J ^a   Leadley, Robert ^a  

^a PFIZER INC   (United States)

Author keywords

Anticoagulants; Antithrombotics; Factor Xa inhibitor; PD 198961; Rabbit; Thrombosis

Indexed keywords

3 (5 AMIDINO 2 HYDROXYPHENYL) 1 [5 (2,6 DIMETHYL 1 PIPERIDINYL)PENTYL] 2(1H) QUINOXALINONE; 3 [4 [2,6 DIMETHYLTETRAHYDRO 1(2H) PYRIDINYL]PENTYL 3 OXO 3,4 DIHYDRO 2 QUINOXALINYL] 4 HYDROXYBENZENECARBOXIMIDAMIDE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; CI 1028; ENOXAPARIN; FERRIC CHLORIDE; LB 30057; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INFUSION; HEMOSTASIS; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RABBIT;

ANIMALS; BLEEDING TIME; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; FERRIC COMPOUNDS; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; QUINOXALINES; RABBITS; SPECIES SPECIFICITY; THROMBOSIS; TIME FACTORS;

EID: 4644339695     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000141475.14007.ab     Document Type: Article

References (29)

1. Hirsh J. Heparin. N Engl J Med. 1991;324:1565-1574.
2. Hirsh J. Oral anticoagulant drugs. N Engl J Med. 1991;324:1865-1875.
3. Chi L, Rogers KL, Uprichard ACG, et al. The therapeutic potential of novel anticoagulants. Exp Opin Investig Drugs. 1997;6:1591-1622.
4. Hauptmann J, Sturzebecher J. Synthetic inhibitors of thrombin and factor Xa: From bench to bedside. Thromb Res. 1999;93:203-241.
5. Antman EM. Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation. 1996;94:911-921.
6. Topol EJ. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 1996;335:775-782.
7. Gold HK, Torres FW, Garabedian HD, et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol. 1993;21:1039-1047.
8. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997;337:447-452.
9. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337:688-698.
10. Mellot MJ, Holahan MA, Lynch JJ, et al. Acceleration of recombinant tissue-type plasminogen activator-induced reperfusion and prevention of reocclusion by recombinant antistatin, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis. Circ Res. 1992;70:1152-1160.
11. Vlasuk GP, Ramjit D, Fujita T, et al. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistatin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis. Thromb Haemost. 1991;65:257-262.
12. Lynch JJ, Sitko GR, Lehman ED, et al. Primary prevention of coronary arterial thrombosis with the factor Xa inhibitor rTAP in a canine electrolytic injury model. Thromb Haemnost. 1995;74:640-645.
13. Schaffer LW, Davidson JT, Vlasuk GP, et al. Antithrombotic efficacy of recombinant tick anticoagulant peptide. A potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis. Circulation. 1991;84:1741-1748.
14. Sinha U. Synthetic inhibitors of coagulation factor Xa. Exp Opin Invest Drugs. 1999;8:567-573.
15. Bauer KA, Eriksson BI, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 2001;345:1305-1310.
16. Eriksson BI, Bauer KA, Lassen MR, et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001;345:1298-1304.
17. Lassen MR, Bauer KA, Eriksson BI, et al. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet. 2002;359:1715-1720.
18. Lyle E, Lewis SD, Lehman ED, et al. Assessment of thrombin inhibitor efficacy in a novel rabbit model of simultaneous arterial and venous thrombosis. Thromb Haemost. 1998;79:656-662.
19. Morishima Y, Tanabe K, Terada Y, et al. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor FXa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants. Thromb Haemost. 1997;78:1366-1371.
20. Wong PC, Quan ML, Crain EJ, et al. Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics. J Pharmacol Exp Ther. 2000;292:351-357.
21. Rogers KL, Chi L, Rapundalo ST, et al. Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis. Basic Res Cardiol. 1999;94:15-22.
22. Taniuchi Y, Sakai Y, Hisamichi N, et al. Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa. Thromb Haemost. 1998;79:543-548.
23. Leadley RJ, Morgan SR, Bentley R, et al. Pharmacodynamic activity and antithrombotic efficacy of RPR120844, a novel inhibitor of coagulation factor Xa. J Cardiovasc Pharmacol. 1999;34:791-799.
24. Wong PC, Crain EJ, Knabb RM, et al. Nonpeptide factor Xa inhibitors II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis. J Pharmacol Exp Ther. 2000;295:212-218.
25. Hara T, Yokoyama A, Ishihara H, et al. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost. 1994;71:314-319.
26. Bostwick JS, Bentley R, Morgan S, et al. RPR120844, a novel, specific inhibitor of coagulation factor Xa inhibits venous thrombosis in the rabbit. Thromb Haemost. 1999;81:157-160.
27. Hara T, Yokoyama A, Morishima Y, et al. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor. Thromb Res. 1995;80:99-104.
28. Abendschein DR, Baum PK, Martin DJ, et al. Effects of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits. J Cardiovasc Pharmacol. 2000;35:796-805.
29. Sato K, Kawasaki T, Taniuchi Y, et al. YM-60828, a novel factor Xa inhibitor: separation of its antithrombotic effects from its prolongation of bleeding time. Eur J Pharmacol. 1997;339:141-146.